All Fulcrum Publications

May 14, 2025

Pociredir, a Potent and Selective EED Inhibitor for the Treatment of Sickle Cell Disease, Induces Target Engagement and Gene Expression Changes that are Specific and Reversible in Wild-Type Mice

Allysa Allen, Caterina Minniti, David Matson, Caroline Sartain, Suchi Raghunathan, Emily Fitz, Briana Steward, Daniel Osorio, Alexander Koch, Billy Stuart, Jeffrey Jacobs

May 14, 2025

Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of the Novel Oral Fetal Hemoglobin (HbF) Inducer Pociredir in Healthy Adults in a Phase 1 Study

Caterina Minniti, Adeyemi Adenola, Thomas Winkler, John Jiang, Utpal Gupta, Iain Fraser

March 19, 2025

Topline Efficacy and Safety Results From REACH: Phase 3 Placebo-Controlled Trial of Losmapimodfor Facioscapulohumeral Muscular Dystrophy (FSHD)

June 24, 2024

Losmapimod, a p38α/βMAPK inhibitor for the Potential Treatment of Patients with FSHD

Jeff Jacobs, PhD

June 15, 2024

An open-label pilot study of losmapimod to evaluate the safety, tolerability, and changes in biomarker and clinical outcome assessments in participants with facioscapulohumeral muscular dystrophy type 1

Joost Kools, Nicol Voermans, John G. Jiang, Olga Mitelman, Michelle L. Mellion, Vivekananda Ramana, Baziel G.M. van Engelen

June 14, 2024

Facioscapulohumeral Muscular Dystrophy (FSHD) Disease Progression and Losmapimod Efficacy Assessed by Reachable Workspace in Both Arms

Joost Kools, MD

June 14, 2024

Interim Results of a Phase 1b Study (PIONEER) of an Oral HbF Inducer, Pociredir, in Sickle Cell Disease

Kenneth Rivlin, MD, PhD; Jae Ahn, PhD; William Engelman, MD; Billy Stuart, PhD; Caterina Minniti, MD

June 13, 2024

Reliability and Validity of Reachable Workspace Total Score with Wrist Weights in Facioscapulohumeral Muscular Dystrophy

Lena Hubig, Adi Eldar-Lissai, Siu Hing Lo, John Jiang, Sarah Acaster, David Cella

June 13, 2024

Safety and Tolerability of Losmapimod for the Treatment of FSHD

Mihaela Levitchi Benea, MD; Marie-Helene Jouvin, MD; Vivekananda Ramana, MD; John Jiang, PhD

June 13, 2024

Characteristics of the Enrolled Population in the Phase 3 REACH Trial in Facioscapulohumeral Muscular Dystrophy (FSHD)

Nicol C Voermans, MD, PhD; Doris G Leung, MD, PhD; Marie-Helene Jouvin, MD; John Jiang, PhD

Next